|
Adverum Biotechnologies, Inc. (ADVM) Évaluation DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Adverum Biotechnologies, Inc. (ADVM) Bundle
Conçu pour la précision, notre calculatrice ADVM DCF vous permet d'évaluer l'évaluation Adverum Biotechnologies, Inc. en utilisant des données financières réelles, offrant une flexibilité complète pour modifier tous les paramètres essentiels pour des projections améliorées.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .3 | .0 | 7.5 | .0 | 3.6 | 1.8 | .9 | .5 | .2 | .1 |
| Revenue Growth, % | 0 | -100 | 0 | -100 | 0 | -50 | -50 | -50 | -50 | -50 |
| EBITDA | -62.9 | -112.2 | -140.9 | -147.9 | -118.3 | -.4 | -.2 | -.1 | .0 | .0 |
| EBITDA, % | -25165.2 | 100 | -1878.6 | 100 | -3287.42 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | 1.6 | 4.2 | 4.6 | 6.5 | 5.6 | 1.7 | .8 | .4 | .2 | .1 |
| Depreciation, % | 629.2 | 100 | 61.93 | 100 | 156.78 | 92.39 | 92.39 | 92.39 | 92.39 | 92.39 |
| EBIT | -64.5 | -116.4 | -145.5 | -154.5 | -124.0 | -.4 | -.2 | -.1 | .0 | .0 |
| EBIT, % | -25794.4 | 100 | -1940.53 | 100 | -3444.19 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 166.0 | 429.7 | 305.2 | 185.6 | 96.5 | 1.8 | .9 | .5 | .2 | .1 |
| Total Cash, percent | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | 5.7 | .0 | .0 | 1.0 | .5 | .2 | .1 | .1 |
| Account Receivables, % | 0 | 100 | 76.12 | 100 | 0 | 55.22 | 55.22 | 55.22 | 55.22 | 55.22 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .7 | .4 | .2 | .1 | .0 |
| Inventories, % | 0 | 100 | 0 | 100 | 0 | 40 | 40 | 40 | 40 | 40 |
| Accounts Payable | 4.1 | 2.8 | 1.4 | 2.2 | 1.9 | 1.3 | .7 | .3 | .2 | .1 |
| Accounts Payable, % | 1641.2 | 100 | 18.49 | 100 | 53.36 | 74.37 | 74.37 | 74.37 | 74.37 | 74.37 |
| Capital Expenditure | -19.2 | -11.8 | -15.1 | -11.8 | -.8 | -.8 | -.4 | -.2 | -.1 | -.1 |
| Capital Expenditure, % | -7698.8 | 100 | -201.64 | 100 | -22.44 | -44.49 | -44.49 | -44.49 | -44.49 | -44.49 |
| Tax Rate, % | 0.91168 | 0.91168 | 0.91168 | 0.91168 | 0.91168 | 0.91168 | 0.91168 | 0.91168 | 0.91168 | 0.91168 |
| EBITAT | -64.5 | -117.5 | -145.5 | -154.5 | -122.9 | -.4 | -.2 | -.1 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -78.1 | -126.5 | -163.2 | -153.3 | -118.3 | -1.8 | .4 | .2 | .1 | .1 |
| WACC, % | 5.75 | 5.75 | 5.75 | 5.75 | 5.72 | 5.74 | 5.74 | 5.74 | 5.74 | 5.74 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 1 | |||||||||
| Present Terminal Value | 1 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | 0 | |||||||||
| Equity Value | 0 | |||||||||
| Diluted Shares Outstanding, MM | 10 | |||||||||
| Equity Value Per Share | 0.01 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Adverum Biotechnologies, Inc. (ADVM) financial data pre-filled to facilitate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.
Key Features
- Comprehensive Financial Data: Access precise pre-loaded historical information and future forecasts for Adverum Biotechnologies, Inc. (ADVM).
- Tailorable Projection Inputs: Modify highlighted fields such as WACC, growth rates, and profit margins to suit your analysis.
- Real-Time Calculations: Automatic adjustments for DCF, Net Present Value (NPV), and cash flow evaluations.
- Interactive Dashboard: User-friendly charts and summaries to help visualize your valuation findings.
- Designed for All Users: An intuitive layout crafted for investors, financial officers, and consultants alike.
How It Works
- Download: Obtain the pre-built Excel file containing Adverum Biotechnologies, Inc.'s (ADVM) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC as needed.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and analyze results immediately.
- Make Decisions: Leverage the valuation insights to inform your investment strategy.
Why Choose Adverum Biotechnologies, Inc. (ADVM) Calculator?
- All-in-One Solution: Combines DCF, WACC, and financial ratio analyses tailored for biotechnology.
- Flexible Inputs: Modify highlighted fields to explore different investment scenarios.
- In-Depth Analysis: Automatically computes Adverum’s intrinsic value and Net Present Value.
- Data-Rich Environment: Access to historical and projected data for reliable analysis.
- Expert-Level Tool: Perfect for biotech analysts, investors, and strategic consultants.
Who Should Use This Product?
- Biotech Investors: Develop comprehensive and accurate valuation models for analyzing ADVM stock.
- Corporate Strategy Teams: Evaluate valuation scenarios to inform strategic decisions within the company.
- Financial Consultants: Deliver precise valuation insights to clients interested in Adverum Biotechnologies, Inc. (ADVM).
- Students and Instructors: Utilize real-world biotech data to enhance learning in financial modeling courses.
- Healthcare Sector Enthusiasts: Gain insights into how biotech firms like Adverum are valued in the stock market.
What the Adverum Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations for Adverum Biotechnologies, Inc. (ADVM).
- Real-World Data: Adverum's historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to Adverum.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results tailored to Adverum Biotechnologies, Inc. (ADVM).
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.